The development of innovative methodologies to identify RNA binders has attracted
enormous attention in chemical biology and drug discovery. Although antibiotics targeting …

The surprising discovery that RNAs are the predominant gene products to emerge from the
human genome catalyzed a renaissance in RNA biology. It is now well-understood that …

Ribonuclease targeting chimeras (RiboTACs) induce degradation of an RNA target by
facilitating an interaction between an RNA and a ribonuclease (RNase). We describe the …

The off-target toxicity of drugs targeted to proteins imparts substantial health and economic
costs. Proteome interaction studies can reveal off-target effects with unintended proteins; …

Myotonic dystrophy type 1 (DM1) is caused by a highly structured RNA repeat expansion, r
(CUG) exp, harbored in the 3′ untranslated region (3′ UTR) of dystrophia myotonica …

A solid-phase DNA-encoded library (DEL) was studied for binding the RNA repeat
expansion r (CUG) exp, the causative agent of the most common form of adult-onset …

Ribonucleases (RNases) cleave and process RNAs, thereby regulating the biogenesis,
metabolism, and degradation of coding and noncoding RNAs. Thus, small molecules …

Although fragment-based drug discovery (FBDD) has been successfully implemented and
well-explored for protein targets, its feasibility for RNA targets is emerging. Despite the …

Introduction The field of RNA-targeted small molecules is rapidly evolving, owing to the
advances in experimental and computational technologies. With the identification of several …

RNA is challenging to target with bioactive small molecules, particularly those of low
molecular weight that bind with sufficient affinity and specificity. In this report, we developed …